Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-07 15:56 | 2025-10-03 | IMRX | Immuneering Corp | Feinberg Peter | Director | BUY | $6.67 | 7,500 | $50,025 | 156,766 |
| 2025-10-07 23:26 | 2025-10-03 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | OPT+S | $25.07 | 10,000 | $250,650 | 11,831 |
| 2025-10-07 23:11 | 2025-10-03 | RNA | Avidity Biosciences, Inc. | Mosbrooker Eric | Officer | OPT+S | $45.38 | 6,562 | $297,771 | 55,000 |
| 2025-10-07 23:26 | 2025-10-03 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | SELL | $25.09 | 42,461 | $1,065,206 | 49,124 |
| 2025-10-08 01:14 | 2025-10-03 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.78 | 20,200 | $35,964 | 1,817,896 |
| 2025-10-08 00:00 | 2025-10-03 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $29.99 | 49,546 | $1,485,790 | 785,480 |
| 2025-10-08 03:22 | 2025-10-06 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $13.99 | 107 | $1,497 | 17,026 |
| 2025-10-07 23:32 | 2025-10-06 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $450.24 | 22,500 | $10,130,438 | 0 |
| 2025-10-08 00:20 | 2025-10-03 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $65.96 | 25,562 | $1,686,024 | 10,332 |
| 2025-10-08 00:20 | 2025-10-03 | PTCT | PTC THERAPEUTICS, INC. | Jacobson Allan Steven | Director | OPT+S | $65.00 | 12,000 | $780,000 | 17,451 |
| 2025-10-08 00:20 | 2025-10-03 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $65.75 | 24,921 | $1,638,548 | 103,901 |
| 2025-10-08 00:20 | 2025-10-03 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | OPT+S | $66.05 | 55,000 | $3,632,976 | 100,625 |
| 2025-10-08 00:08 | 2025-10-07 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $60.56 | 2,000 | $121,120 | 140,610 |
| 2025-10-06 23:00 | 2025-10-03 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $837.93 | 192,404 | $161,220,410 | 94,836,978 |
| 2025-10-06 22:15 | 2025-10-02 | ARQT | Arcutis Biotherapeutics Inc. | Edwards Larry Todd | Officer | SELL | $20.04 | 4,504 | $90,263 | 179,324 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Swanton Robert Charles | Director | SELL | $8.55 | 102 | $872 | 15,487 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Hannay Michael Charles Ferguson | Officer | SELL | $8.40 | 723 | $6,076 | 53,102 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Thompson Travis Alvin | Officer | SELL | $8.40 | 324 | $2,723 | 31,197 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Young Alethia | Officer | SELL | $8.51 | 482 | $4,103 | 44,704 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Milnes Alistair | Officer | SELL | $8.40 | 2,125 | $17,860 | 93,377 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Lee Kevin | Director, Officer | SELL | $8.41 | 5,494 | $46,182 | 475,310 |
| 2025-10-06 23:45 | 2025-10-02 | BCYC | BICYCLE THERAPEUTICS PLC | Skynner Michael | Officer | SELL | $8.41 | 1,802 | $15,147 | 118,277 |
| 2025-10-07 00:13 | 2025-10-02 | OCUL | OCULAR THERAPEUTIX, INC | Kaiser Peter | Officer | SELL | $11.03 | 9,653 | $106,473 | 194,440 |
| 2025-10-07 00:10 | 2025-10-02 | OCUL | OCULAR THERAPEUTIX, INC | Heier Jeffrey S. | Officer | SELL | $11.04 | 10,502 | $115,942 | 249,409 |
| 2025-10-06 16:12 | 2025-10-03 | PMN | ProMIS Neurosciences Inc. | Milbury Max A. | BUY | $0.49 | 30,392 | $14,929 | 45,389 | |
| 2025-10-07 00:35 | 2025-10-03 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $447.95 | 8,000 | $3,583,612 | 130 |
| 2025-10-06 23:27 | 2025-10-06 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | SELL | $60.00 | 6,757 | $405,420 | 9,778 |
| 2025-10-07 00:54 | 2025-10-02 | AIMD | Ainos Inc. | Taiwan Carbon Nano Technology Corp | 10% owner | SELL | $3.59 | 2,000 | $7,170 | 1,044,206 |
| 2025-10-03 23:00 | 2025-10-02 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $821.55 | 112,596 | $92,503,356 | 95,029,382 |
| 2025-10-03 23:28 | 2025-10-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $85.48 | 20,000 | $1,709,512 | 61,734 |
| 2025-10-04 01:15 | 2025-10-01 | ARWR | Arrowhead Pharmaceuticals Inc. | Hamilton James C | Officer | SELL | $35.00 | 20,000 | $700,000 | 212,122 |
| 2025-10-04 00:02 | 2025-10-01 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $19.66 | 45,000 | $884,651 | 846,440 |
| 2025-10-04 00:01 | 2025-10-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | OPT+S | $18.92 | 10,000 | $189,227 | 99,744 |
| 2025-10-03 23:07 | 2025-10-02 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Biller Jonathan | Officer | SELL | $404.21 | 694 | $280,522 | 15,653 |
| 2025-10-03 23:30 | 2025-10-01 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | OPT+S | $47.76 | 12,500 | $596,979 | 196,898 |
| 2025-10-03 23:20 | 2025-10-02 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $34.25 | 456 | $15,617 | 17,184 |
| 2025-10-03 23:41 | 2025-10-01 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | OPT+S | $41.81 | 5,000 | $209,050 | 66,270 |
| 2025-10-03 23:25 | 2025-10-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $23.64 | 5,343 | $126,316 | 13,126 |
| 2025-10-03 23:56 | 2025-10-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $6.30 | 362 | $2,279 | 10,046 |
| 2025-10-04 00:25 | 2025-10-01 | CARM | Carisma Therapeutics Inc. | Klichinsky Michael | Officer | SELL | $0.26 | 484,347 | $124,332 | 0 |
| 2025-10-03 23:30 | 2025-08-08 | ASMB | Assembly Biosciences Inc. | GILEAD SCIENCES, INC. | 10% owner | BUY | $0.00 | 2,295,920 | $0 | 4,505,391 |
| 2025-10-04 03:24 | 2025-10-02 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $14.13 | 500 | $7,065 | 202,133 |
| 2025-10-03 23:18 | 2025-10-02 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $48.06 | 1,904 | $91,506 | 1,161,233 |
| 2025-10-03 23:45 | 2025-10-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $179.44 | 467 | $83,800 | 45,055 |
| 2025-10-04 04:35 | 2025-10-01 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director | SELL | $2.41 | 123,366 | $296,794 | 8,260 |
| 2025-10-04 04:27 | 2025-10-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | SELL | $137.01 | 5,500 | $753,560 | 408,826 |
| 2025-10-04 00:14 | 2025-10-02 | ALNY | Alnylam Pharmaceuticals Inc. | Poulton Jeffrey V. | Officer | SELL | $452.05 | 3,821 | $1,727,283 | 54,052 |
| 2025-10-04 00:14 | 2025-10-02 | ALNY | Alnylam Pharmaceuticals Inc. | Greenstreet Yvonne | Director, Officer | SELL | $452.05 | 8,924 | $4,034,084 | 65,409 |
| 2025-10-04 00:14 | 2025-10-02 | ALNY | Alnylam Pharmaceuticals Inc. | Tanguler Tolga | Officer | SELL | $452.05 | 1,405 | $635,126 | 27,438 |
| 2025-10-04 00:13 | 2025-10-02 | ALNY | Alnylam Pharmaceuticals Inc. | Fitzgerald Kevin Joseph | Officer | SELL | $452.05 | 2,441 | $1,103,451 | 25,231 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.